Rubric : Topical
New therapeutic options in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemiaДата: 2024-04-11
Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: а retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancerТ. 13, №4 (52)
New stage in personalized breast cancer therapy: a chance for recovery
How to improve the diagnosis and treatment of patients with prostate cancer in Ukraine? Results of the 2023 surveyТ. 13, №4 (52)
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Modern approaches to the diagnosis and treatment of lymphoproliferative diseases
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesotheliomaAuthor:Nemish I.L. Т. 13, № 3 (51)
Talazoparib in the treatment of breast cancer. Analysis of the real-world evidence
New stage in personalized breast cancer therapy: a chance for recovery
Modern tactics of treatment of relapsed/refractory multiple myelomaAuthor:Nemish I.L. Т. 13, № 3 (51)
Induction targeted therapy with tyrosine kinase inhibitors in the treatment of EGFR-positive non-small cell lung cancer. Clinical case and discussion of features of therapeutic «targeted» tumor pathomorphosisAuthors: Sukhoversha O.A. Tsyhankov K.V. Kuzhevskyi I.V. Koval S.S. Т. 13, № 2 (50)
Clinical characteristics, treatment characteristics, and endpoints assessed in real-world clinical practice of talazoparib in patients with HER2-negative BRCA-associated breast cancerAuthor:Huyvanyuk O.A. Т. 13, № 2 (50)
The role of T790M mutation in first- and second-line therapy of patients with EGFR-positive non-small cell lung cancerAuthors: Storozhenko S.A. Shparyk Ya.V. Т. 13, № 1 (49)
Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer
